Isolators pharmaceutical manufacture

There are circumstances in which it is not possible to obtain the required enantiomer at manufacturing scale either by synthesis or isolation, e.g. because of difficulties with scale-up or failure to obtain material in a suitable physical form for pharmaceutical manufacture. In such cases, all the experimental results available should be described and the reason for the failure given. Likewise, if enantiomeric material could not be obtained for preclinical and clinical studies (see below), this should also be discussed. Advances in preparative techniques should eventually make this scenario less common. 

A decision not to perform the review (e.g., evidence that code is developed under a quality system and formal reviews have already been conducted and reported) should be documented in the project validation plan, complete with the rationale. It is recognized that under its software quality assurance program the supplier may conduct similar examination of the software using only internal resource. Considering GMP implications, the pharmaceutical manufacturer would normally require that the software designer or programmer does not carry out any software review in isolation. 

In industry, the BSC is used to conduct small batch sterile-fill operations, manipulation (weighing and pouring), isolation of hazardous materials, and in QA/QC testing applications. All classes of BSC are encountered in pharmaceutical manufacturing operations for a wide variety of processing applications. 

Clothing the operator completely in an impervious plastic suit represents the ultimate in personal protection and has the additional merit of isolating the product completely from operator and such suits have been used to maintain sterility during pharmaceutical manufacture. Isolator suits should not be used as the primary means of protecting the operator but must be used only in combination with effective techniques for safely dispensing, handling and freeze-drying hazardous products. 

Kurokawa S, Elix JA, Watson PL, Sargent MV (1971) Parmelia notatay a new lichen species producing two new depsidones. J Jpn Bot 46 33-38 Kutney JP, Sanchez IH, Yee TH (1974) Mass spectral fragmentation studies in usnic acid and related compounds. Org Mass Spectrom 8 129-146 Laake Oy (1960) Institutional advertising of the La e Oy Pharmaceutical Manufacturers, Turku, Finland Lajide L (1984) Lichen depsides, depsidones and diphenyl ethers isolation, structure determination and synthesis. Thesis, Australian National Univ, Canberra Lam JKK, Sargent MV, Elix JA, Smith DO N (1972) Synthesis of valsarin and 5,7-dichloroemodin. J Chem Soc Perkin Trans 1 1466-1470... 

Neiger J. (1997) Life with the UK pharmaceutical isolator guidelines a manufacturer s viewpoint. Eur... 

The natural bioburden in a well-maintained pharmaceutical parenteral manufacturing plant is quite low, often to the point that it is difficult to isolate and propagate plant bioburden for sterilization studies. Nevertheless, it is still important to characterize the microbiological bioburden in the process and then monitor it at regular intervals. 

Salts of the reaction product, nitroethanedithioic acid, are intermediates in manufacture of pharmaceuticals. They are explosive and are to be avoided if not isolated. The free acid will surely be unstable, but not necessarily explosive. 

Impurities in drug substances and drug products continue to be a source of great concern, discussion, debate, and research. " These concerns and debates typically center on the potential safety risks associated with impurities due to contamination and the setting of acceptance criteria. However, the bulk of the work being performed in the pharmaceutical industry, with respect to impurities, is focused on the isolation, identification, qualification and quantification of impurities that are found as a result of the manufacturing process or through chemical decomposition. On the... 

Pharmaceutical substances form the backbone of modern medicinal therapy. Most traditional pharmaceuticals are low molecular mass organic chemicals (Table 1.1). Although some (e.g. aspirin) were originally isolated from biological sources, most are now manufactured by direct chemical synthesis. Two types of manufacturing companies thus comprise the traditional pharmaceutical sector the chemical synthesis plants, which manufacture the raw chemical ingredients in bulk quantities, and the finished product pharmaceutical facilities, which purchase these raw bulk ingredients, formulate them into final pharmaceutical products, and supply these products to the end-user. 

---